There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Most treatment advances in PD have been based on restoring dopaminergic input. The
development of levodopa was the first breakthrough and, since then, other compounds
have been developed. Each antiparkinsonian medication has its own profile of efficacy
and adverse effects, and these can largely be explained by their modes of action.
As patients receive a number of different compounds, physicians should be aware of
the differences of agents and understand how these differences may relate to clinical
practice. This article reviews the three main classes of dopaminergic PD therapy (levodopa,
monoamine oxidase inhibitors and dopamine agonists).